Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma

The immunomodulatory drug lenalidomide is used in patients with follicular lymphoma (FL) with the aim of stimulating T-cell antitumor immune response. However, little is known about the effects of lenalidomide on T-cell biology in vivo in patients with FL. We thus undertook an extensive longitudinal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Ménard, Cédric, Rossille, Delphine, Dulong, Joelle, Nguyen, Tien-Tuan, Papa, Ilenia, Latour, Maelle, Bescher, Nadège, Bezier, Isabelle, Chouteau, Myriam, Fest, Thierry, Houot, Roch, Morschhauser, Franck, Tarte, Karin
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8095143/
https://ncbi.nlm.nih.gov/pubmed/33877296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003774
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados